BEST UNLIMITED TURBO LONG CERTIFICATE - BRISTOL-MYERS SQUIBB | Market Closed - Euronext Paris 12:30:01 2024-05-14 pm EDT | ||
| 0.58 EUR | -13.43% |
|
| Current month | -3.28% | ||
| 1 month | -59.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-14 | 0.58 | -13.43% |
| 24-05-13 | 0.67 | +11.67% |
| 24-05-10 | 0.6 | +33.33% |
| 24-05-09 | 0.45 | +4.65% |
| 24-05-08 | 0.43 | -15.69% |
Real-time Euronext Paris
Last update May 14, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| D326S | |
| ISIN | DE000SU2JJ11 |
| Date issued | 2023-11-21 |
| Strike | 41.75 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.515 € |
|---|---|
| Lowest since issue | 0.37 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
45.06
USD
Average target price
53.19
USD
Spread / Average Target
+18.05%
- Stock Market
- Certificates
- D326S Certificat